United States securities and exchange commission logo





                           August 2, 2021

       Brian Emes
       Chief Financial Officer
       CM Life Sciences II Inc.
       c/o Corvex Management LP
       667 Madison Avenue
       New York, NY 10065

                                                        Re: CM Life Sciences II
Inc.
                                                            Amendment No. 2 to
Registration Statement on Form S-4
                                                            Filed July 22, 2021
                                                            File No. 333-256127

       Dear Mr. Emes:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our July
12, 2021 letter.

       Amendment No. 2 to Registration Statement on Form S-4 Filed July 22,
2021

       Background of the Business Combination, page 147

   1.                                                   We note your response
to comment 8. Please disclose how management chose the seven
                                                        potential acquisition
targets and include information on why management determined not
                                                        to pursue discussions
with them.
   2.                                                   We note your response
to comment 9. Please disclose the date(s) on which CM Life
                                                        Sciences, Inc. ceased
conversions with SomaLogic and entered into an exclusivity
                                                        arrangement with the
other business combination target.
 Brian Emes
FirstName  LastNameBrian
CM Life Sciences II Inc. Emes
Comapany
August     NameCM Life Sciences II Inc.
       2, 2021
August
Page 2 2, 2021 Page 2
FirstName LastName
Description of Securities
Forum Selection Clause, page 282

3.       We note that your Amended & Restated Certificate of Incorporation,
which is included in
         your exhibit index as exhibit 3.1, contains an exclusive forum
provision. Please revise
         your Description of Securities disclosure on page 282 to acknowledge
the exclusive forum
         provision in your Amended & Restated Certificate of Incorporation.
       Please contact Cara Wirth at (202) 551-7127 or Dietrich King at (202)
551-8071 with any
questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Trade &
Services
cc:      Joel Rubinstein